Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro

Cancer Letters

Volumn 306, Issue 1, 2011, Pages 34-42

  Yin, Haipeng ^a,b   Xie, Fengxiang ^a   Zhang, Jiao ^c   Yang, Yongmei ^a   Deng, Biping ^a   Sun, Jintang ^a   Wang, Qingjie ^a   Qu, Xun ^a   Mao, Haiting ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

5 Fluorouracil; Hepatocellular carcinoma; Interferon ; Intracellular calcium; Mitochondrial apoptosis; Proliferation

Indexed keywords

CALCIUM; CASPASE 8; CYTOCHROME C; FAS ANTIGEN; FLUOROURACIL; PROTEIN BID; RECOMBINANT ALPHA INTERFERON AD;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG POTENTIATION; GENE; GENE BCL XL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BCL-X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CALCIUM; CARCINOMA, HEPATOCELLULAR; CASPASE 8; CELL LINE; CELL PROLIFERATION; CYTOCHROMES C; DISEASE PROGRESSION; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MITOCHONDRIA;

EID: 79955469207     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.017     Document Type: Article

References (35)

1. Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. Journal of Hepatology 2008, 48(Suppl. 1):S20-37.
2. Brechot C., Jaffredo F., Lagorce D., Gerken G., Meyer zum Buschenfelde K., Papakonstontinou A., Hadziyannis S., Romeo R., Colombo M., Rodes J., Bruix J., Williams R., Naoumov N. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. Journal of Hepatology 1998, 29:173-183.
3. Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleveland Clinic Journal of Medicine 2009, 76(Suppl. 3):S6-9.
4. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. Journal of Gastroenterology 2009, 44(Suppl. 19):136-141.
5. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. Apmis 1995, 103:161-179.
6. Romerio F., Riva A., Zella D. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism. British Journal of Cancer 2000, 83:532-538.
7. Platanias L.C. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacology & Therapeutics 2003, 98:129-142.
8. Sakon M., Nagano H., Dono K., Nakamori S., Umeshita K., Yamada A., Kawata S., Imai Y., Iijima S., Monden M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002, 94:435-442.
9. Patt Y.Z., Hassan M.M., Lozano R.D., Brown T.D., Vauthey J.N., Curley S.A., Ellis L.M. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. Journal of Clinical Oncology 2003, 21:421-427.
10. Hong S.K., Kwak C., Lee S.E. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma. Urology 2005, 66:518-522.
11. Kojiro S., Yano H., Ogasawara S., Momosaki S., Takemoto Y., Nishida N., Kojiro M. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. Journal of Gastroenterology and Hepatology 2006, 21:129-137.
12. Wadler S., Wiernik P.H. Partial reversal of doxorubicin resistance by forskolin and 1, 9-dideoxyforskolin in murine sarcoma S180 variants. Cancer Research 1988, 48:539-543.
13. Kelsen D., Lovett D., Wong J., Saltz L., Buckley M., Murray P., Heelan R., Lightdale C. Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. Journal of Clinical Oncology 1992, 10:269-274.
14. Lee K.H., Lee J.S., Suh C., Lee Y.S., Min Y.I., Ahn S.H., Park K.C., Kim S.K., Kim S.H. Combination of 5-fluorouracil and recombinant interferon alpha-2B in advanced gastric cancer. A phase I study. American Journal of Clinical Oncology 1992, 15:141-145.
15. Kondo M., Nagano H., Wada H., Damdinsuren B., Yamamoto H., Hiraoka N., Eguchi H., Miyamoto A., Yamamoto T., Ota H., Nakamura M., Marubashi S., Dono K., Umeshita K., Nakamori S., Sakon M., Monden M. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clinical Cancer Research 2005, 11:1277-1286.
16. Nakamura M., Nagano H., Sakon M., Yamamoto T., Ota H., Wada H., Damdinsuren B., Noda T., Marubashi S., Miyamoto A., Takeda Y., Umeshita K., Nakamori S., Dono K., Monden M. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. Journal of Hepatology 2007, 46:77-88.
17. Ota H., Nagano H., Sakon M., Eguchi H., Kondo M., Yamamoto T., Nakamura M., Damdinsuren B., Wada H., Marubashi S., Miyamoto A., Dono K., Umeshita K., Nakamori S., Wakasa K., Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. British Journal of Cancer 2005, 93:557-564.
18. Nagano H., Miyamoto A., Wada H., Ota H., Marubashi S., Takeda Y., Dono K., Umeshita K., Sakon M., Monden M. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 2007, 110:2493-2501.
19. Wada H., Nagano H., Yamamoto H., Arai I., Ota H., Nakamura M., Damdinsuren B., Noda T., Marubashi S., Miyamoto A., Takeda Y., Umeshita K., Doki Y., Dono K., Nakamori S., Sakon M., Monden M. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncology Reports 2007, 18:801-809.
20. Oie S., Ono M., Fukushima H., Hosoi F., Yano H., Maruyama Y., Kojiro M., Terada T., Hirano K., Kuwano M., Yamada Y. Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells. Molecular Cancer Therapeutics 2007, 6:2310-2318.
21. Yuan J., Murrell G.A., Trickett A., Wang M.X. Involvement of cytochrome c release and caspase-3 activation in the oxidative stress-induced apoptosis in human tendon fibroblasts. Biochimica et Biophysica Acta 2003, 1641:35-41.
22. Komorizono Y., Kohara K., Oketani M., Maeda M., Shibathou T., Shigenobu S., Hiramine Y., Yamasaki N., Arima T., Kazuaki I., Arima T. Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Digestive Diseases and Sciences 2003, 48:877-881.
23. Yuen M.F., Ooi C.G., Hui C.K., Wong W.M., Wong B.C., Chan A.O., Lai C.L. A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 2003, 97:2776-2782.
24. Dou J., Iwashita Y., Sasaki A., Kai S., Hirano S., Ohta M., Kitano S. Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression. Liver International 2005, 25:148-152.
25. Schwartz E.L., Hoffman M., O'Connor C.J., Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochemical and Biophysical Research Communications 1992, 182:1232-1239.
26. Eguchi H., Nagano H., Yamamoto H., Miyamoto A., Kondo M., Dono K., Nakamori S., Umeshita K., Sakon M., Monden M. Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clinical Cancer Research 2000, 6:2881-2890.
27. Hagiwara S., Kudo M., Nakatani T., Sakaguchi Y., Nagashima M., Fukuta N., Kimura M., Hayakawa S., Munakata H. Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. British Journal of Cancer 2007, 97:1532-1537.
28. Wada H., Nagano H., Yamamoto H., Noda T., Murakami M., Kobayashi S., Marubashi S., Eguchi H., Takeda Y., Tanemura M., Umeshita K., Doki Y., Mori M. Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer 2009, 9:361.
29. Yamamoto T., Nagano H., Sakon M., Wada H., Eguchi H., Kondo M., Damdinsuren B., Ota H., Nakamura M., Wada H., Marubashi S., Miyamoto A., Dono K., Umeshita K., Nakamori S., Yagita H., Monden M. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. Clinical Cancer Research 2004, 10:7884-7895.
30. Damdinsuren B., Nagano H., Sakon M., Kondo M., Yamamoto T., Umeshita K., Dono K., Nakamori S., Monden M. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Annals of Surgical Oncology 2003, 10:1184-1190.
31. Renz A., Berdel W.E., Kreuter M., Belka C., Schulze-Osthoff K., Los M. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood 2001, 98:1542-1548.
32. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
33. Jaffe L.F. A calcium-based theory of carcinogenesis. Advances in Cancer Research 2005, 94:231-263.
34. Hajnoczky G., Csordas G., Das S., Garcia-Perez C., Saotome M., Sinha Roy S., Yi M. Mitochondrial calcium signalling and cell death: approaches for assessing the role of mitochondrial Ca2+ uptake in apoptosis. Cell Calcium 2006, 40:553-560.
35. Lucas M., Diaz P. Thapsigargin-induced calcium entry and apoptotic death of neutrophils are blocked by activation of protein kinase C. Pharmacology 2001, 63:191-196.